Skip to main content

Advertisement

SpringerLink
Log in

Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma

  • Progress in Hematology
  • T-cell lymphoma
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Adult T-cell leukemia–lymphoma (ATL) is classified into four clinical subtypes: acute, lymphoma, chronic, and smoldering. Chronic ATL is further divided into unfavorable and favorable chronic types according to serum lactate dehydrogenase, blood urea nitrogen, and serum albumin values. Acute, lymphoma, and unfavorable chronic types are categorized as aggressive ATL, whereas favorable chronic and smoldering types are categorized as indolent ATL. Intensive chemotherapy alone is not sufficient to prevent relapse of aggressive ATL. Allogeneic hematopoietic stem cell transplantation is a potential therapeutic option to cure aggressive ATL in younger patients. Reduced-intensity conditioning regimens have decreased transplantation-related mortality, and increased donor availability has dramatically improved transplant access. New agents, including mogamulizumab, brentuximab vedotin, tucidinostat, and valemetostat, have recently become available for patients with aggressive ATL in Japan. Here, I provide an overview of recent advances in therapeutic strategies for ATL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322. https://doi.org/10.3389/fmicb.2012.00322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. de Thé G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses. 1993;9(5):381–6. https://doi.org/10.1089/aid.1993.9.381.

    Article  PubMed  Google Scholar 

  3. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388. https://doi.org/10.3389/fmicb.2012.00388.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058–68. https://doi.org/10.1038/sj.onc.1208968.

    Article  CAS  PubMed  Google Scholar 

  5. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79(3):428–37. https://doi.org/10.1111/j.1365-2141.1991.tb08051.x.

    Article  CAS  PubMed  Google Scholar 

  6. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570–7. https://doi.org/10.1182/blood-2015-03-632489.

    Article  CAS  PubMed  Google Scholar 

  7. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30(14):1635–40. https://doi.org/10.1200/jco.2011.38.2101.

    Article  CAS  PubMed  Google Scholar 

  8. Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166(5):739–48. https://doi.org/10.1111/bjh.12962.

    Article  PubMed  Google Scholar 

  9. Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1258–65. https://doi.org/10.3324/haematol.2017.164996.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215–25. https://doi.org/10.1182/blood-2017-01-761874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130(1):39–47. https://doi.org/10.1182/blood-2017-01-757542.

    Article  CAS  PubMed  Google Scholar 

  12. Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164–70. https://doi.org/10.1007/bf02983215.

    Article  CAS  PubMed  Google Scholar 

  13. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113(2):375–82. https://doi.org/10.1046/j.1365-2141.2001.02737.x.

    Article  CAS  PubMed  Google Scholar 

  14. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–64. https://doi.org/10.1200/jco.2007.11.9958.

    Article  CAS  PubMed  Google Scholar 

  15. Toyoda K, Tsukasaki K, Machida R, Kadota T, Fukushima T, Ishitsuka K, et al. Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801. Br J Haematol. 2019;186(3):440–7. https://doi.org/10.1111/bjh.15950.

    Article  CAS  PubMed  Google Scholar 

  16. Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Owatari S, et al. VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis. Bone Marrow Transplant. 2019;54(9):1399–405. https://doi.org/10.1038/s41409-019-0446-z.

    Article  CAS  PubMed  Google Scholar 

  17. Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-cell leukemia-lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677–87. https://doi.org/10.1200/jco.18.00501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607–20. https://doi.org/10.1182/bloodadvances.2017011106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, et al. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: a nationwide hospital-based study. Cancer Sci. 2020;111(12):4567–80. https://doi.org/10.1111/cas.14658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Makiyama J, Imaizumi Y, Tsushima H, Taniguchi H, Moriwaki Y, Sawayama Y, et al. Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience. Int J Hematol. 2014;100(5):464–72. https://doi.org/10.1007/s12185-014-1665-0.

    Article  CAS  PubMed  Google Scholar 

  21. Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51(2):205–11. https://doi.org/10.1038/bmt.2015.265.

    Article  CAS  PubMed  Google Scholar 

  22. Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105(10):4143–5. https://doi.org/10.1182/blood-2004-11-4193.

    Article  CAS  PubMed  Google Scholar 

  23. Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant. 2008;14(6):702–8. https://doi.org/10.1016/j.bbmt.2008.03.010.

    Article  CAS  PubMed  Google Scholar 

  24. Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant. 2011;46(1):116–8. https://doi.org/10.1038/bmt.2010.92.

    Article  CAS  PubMed  Google Scholar 

  25. Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120(8):1734–41. https://doi.org/10.1182/blood-2012-03-414490.

    Article  CAS  PubMed  Google Scholar 

  26. Inoue Y, Nakano N, Fuji S, Eto T, Kawakita T, Suehiro Y, et al. Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. Bone Marrow Transplant. 2021;56(12):2964–74. https://doi.org/10.1038/s41409-021-01445-0.

    Article  CAS  PubMed  Google Scholar 

  27. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369–76. https://doi.org/10.1182/blood-2009-10-247510.

    Article  CAS  PubMed  Google Scholar 

  28. Nakamura T, Oku E, Nomura K, Morishige S, Takata Y, Seki R, et al. Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute. Int J Hematol. 2012;96(5):657–63. https://doi.org/10.1007/s12185-012-1177-8.

    Article  PubMed  Google Scholar 

  29. Fukushima T, Itonaga H, Moriuchi Y, Yoshida S, Taguchi J, Imaizumi Y, et al. Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki transplantation Network. Int J Hematol. 2013;97(4):485–90. https://doi.org/10.1007/s12185-013-1307-y.

    Article  PubMed  Google Scholar 

  30. Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, et al. Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biol Blood Marrow Transplant. 2014;20(12):1968–74. https://doi.org/10.1016/j.bbmt.2014.08.012.

    Article  PubMed  Google Scholar 

  31. Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5(20):4156–66. https://doi.org/10.1182/bloodadvances.2021004932.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, et al. A phase I/II multicenter Trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia/lymphoma. Transplant Cell Ther. 2021;27(11):92817. https://doi.org/10.1016/j.jtct.2021.07.010.

    Article  CAS  Google Scholar 

  33. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744–8. https://doi.org/10.1056/nejm199506293322603.

    Article  CAS  PubMed  Google Scholar 

  34. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749–51. https://doi.org/10.1056/nejm199506293322604.

    Article  CAS  PubMed  Google Scholar 

  35. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177–83. https://doi.org/10.1200/jco.2010.28.0669.

    Article  CAS  PubMed  Google Scholar 

  36. Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696–701. https://doi.org/10.1200/jco.2011.35.5578.

    Article  CAS  PubMed  Google Scholar 

  37. Guery R, Suarez F, Lanternier F, Bougnoux ME, Lecuyer H, Avettand-Fenoel V, et al. Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa. Ann Hematol. 2021;100(11):2813–24. https://doi.org/10.1007/s00277-021-04622-9.

    Article  CAS  PubMed  Google Scholar 

  38. Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, Yamada S, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011;117(15):3961–7. https://doi.org/10.1182/blood-2010-11-316794.

    Article  CAS  PubMed  Google Scholar 

  39. Kameda T, Shide K, Tahira Y, Sekine M, Sato S, Ishizaki J, et al. Prognosis of indolent adult T-Cell leukemia/lymphoma. Viruses. 2022. https://doi.org/10.3390/v14040710.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, et al. Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. Int J Hematol. 2023;117(2):206–15. https://doi.org/10.1007/s12185-022-03473-y.

    Article  CAS  PubMed  Google Scholar 

  41. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42. https://doi.org/10.1200/jco.2011.37.3472.

    Article  CAS  PubMed  Google Scholar 

  42. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–82. https://doi.org/10.1111/bjh.13338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, et al. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2019;184(3):479–83. https://doi.org/10.1111/bjh.15123.

    Article  PubMed  Google Scholar 

  44. Shichijo T, Nosaka K, Tatetsu H, Higuchi Y, Endo S, Inoue Y, et al. Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. Br J Haematol. 2022;198(6):983–7. https://doi.org/10.1111/bjh.18281.

    Article  CAS  PubMed  Google Scholar 

  45. Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758–61. https://doi.org/10.1182/blood-2018-02-835991.

    Article  CAS  PubMed  Google Scholar 

  46. Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, et al. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica. 2022;107(10):2418–31. https://doi.org/10.3324/haematol.2021.280352.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–33. https://doi.org/10.1200/jco.2016.67.8250.

    Article  PubMed  Google Scholar 

  48. Sakamoto H, Itonaga H, Sawayama Y, Furumoto T, Fujioka M, Chiwata M, et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162–70. https://doi.org/10.1002/hon.2712.

    Article  CAS  PubMed  Google Scholar 

  49. Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, et al. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54(2):338–42. https://doi.org/10.1038/s41409-018-0291-5.

    Article  CAS  PubMed  Google Scholar 

  50. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–50. https://doi.org/10.1126/science.1177319.

    Article  CAS  PubMed  Google Scholar 

  51. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–35. https://doi.org/10.1038/leu.2012.119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086–93. https://doi.org/10.1200/jco.2016.67.7732.

    Article  CAS  PubMed  Google Scholar 

  53. Tanaka T, Inamoto Y, Ito A, Watanabe M, Takeda W, Aoki J, et al. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation. Hematol Oncol. 2022. https://doi.org/10.1002/hon.3115.

    Article  PubMed  Google Scholar 

  54. Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983–6. https://doi.org/10.1182/blood-2014-07-584953.

    Article  CAS  PubMed  Google Scholar 

  55. Nakashima M, Yamochi T, Watanabe M, Uchimaru K, Utsunomiya A, Higashihara M, et al. CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1-infected Individuals. Clin Cancer Res. 2018;24(21):5445–57. https://doi.org/10.1158/1078-0432.ccr-18-0268.

    Article  CAS  PubMed  Google Scholar 

  56. Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–40. https://doi.org/10.1016/s0140-6736(18)32984-2.

    Article  CAS  PubMed  Google Scholar 

  57. Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790–802. https://doi.org/10.1182/blood-2015-08-662593.

    Article  CAS  PubMed  Google Scholar 

  58. Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-37.e7. https://doi.org/10.1016/j.celrep.2019.10.083.

    Article  CAS  PubMed  Google Scholar 

  59. Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2022. https://doi.org/10.1182/blood.2022016862.

    Article  PubMed  Google Scholar 

  60. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51. https://doi.org/10.1038/nrc1779.

    Article  CAS  PubMed  Google Scholar 

  61. Sun Y, Hong JH, Ning Z, Pan D, Fu X, Lu X, et al. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol. 2022;13:932914. https://doi.org/10.3389/fphar.2022.932914.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: phase IIb results. Cancer Sci. 2022;113(8):2778–87. https://doi.org/10.1111/cas.15431.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20(20):5217–25. https://doi.org/10.1158/1078-0432.ccr-14-0572.

    Article  CAS  PubMed  Google Scholar 

  64. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. https://doi.org/10.1016/j.cell.2015.03.030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers. Nature. 2016;534(7607):402–6. https://doi.org/10.1038/nature18294.

    Article  CAS  PubMed  Google Scholar 

  66. Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947–8. https://doi.org/10.1056/NEJMc1803181.

    Article  PubMed  Google Scholar 

  67. Ishitsuka K, Utsunomiya A, Ishida T. PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma. N Engl J Med. 2018;379(7):695. https://doi.org/10.1056/NEJMc1807852.

    Article  PubMed  Google Scholar 

  68. Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145(2):173–9. https://doi.org/10.1111/j.1365-2141.2009.07606.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Sharma K, Janik JE, O’Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, et al. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Clin Cancer Res. 2017;23(1):35–42. https://doi.org/10.1158/1078-0432.ccr-16-1022.

    Article  CAS  PubMed  Google Scholar 

  70. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113(26):6528–32. https://doi.org/10.1182/blood-2009-03-211821.

    Article  CAS  PubMed  Google Scholar 

  71. Marçais A, Cook L, Witkover A, Asnafi V, Avettand-Fenoel V, Delarue R, et al. Arsenic trioxide (As(2)O(3)) as a maintenance therapy for adult T cell leukemia/lymphoma. Retrovirology. 2020;17(1):5. https://doi.org/10.1186/s12977-020-0513-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169(3):356–67. https://doi.org/10.1111/bjh.13302.

    Article  CAS  PubMed  Google Scholar 

  73. Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, et al. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100. Blood. 2020;136(7):871–84. https://doi.org/10.1182/blood.2019003084.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan

    Hiroo Katsuya

Authors
  1. Hiroo Katsuya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroo Katsuya.

Ethics declarations

Conflict of interest

The author declares that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katsuya, H. Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma. Int J Hematol 117, 512–522 (2023). https://doi.org/10.1007/s12185-023-03572-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-023-03572-4

Keywords

Search

Navigation